|
WO2021081262A1
|
|
Systems and methods for auto-inoculation in seed train and production processes
|
|
WO2021081277A1
|
|
Dosing regimens for treating or preventing c5-associated diseases
|
|
WO2021077106A1
|
|
Site-specific quantitation of drug conjugations
|
|
WO2021076735A1
|
|
Methods for characterizing host-cell proteins
|
|
WO2021072230A1
|
|
Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation
|
|
US2021102942A1
|
|
High-throughput method to screen cognate T cell and epitope reactivities in primary human cells
|
|
US2021100227A1
|
|
Crnn loss of function rodent model
|
|
US2021102951A1
|
|
Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis
|
|
WO2021062198A1
|
|
Single cell rna-seq data processing
|
|
US2021008181A1
|
|
Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors
|
|
WO2021061790A1
|
|
Systems and methods for chromatography use and regeneration
|
|
US2021087272A1
|
|
Anti-ptcra antibody-drug conjugates and uses thereof
|
|
WO2021055486A1
|
|
Lc-ms methods for antibody isotyping and quantification
|
|
WO2021055483A1
|
|
Universal modular test fixture
|
|
WO2021055350A1
|
|
Radiolabeled met binding proteins for immuno-pet imaging
|
|
WO2021050940A1
|
|
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
|
WO2021035028A2
|
|
Formulation optimization for bispecific antibodies
|
|
WO2021030680A1
|
|
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
WO2021034639A1
|
|
High concentration anti-c5 formulations
|
|
WO2021030358A1
|
|
Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
|
